Skip to Main Content
Contribute Try STAT+ Today
Trending:
First Opinion
Coronavirus
Biotech
Health

STAT+ Latest

Columns: Adam’s TakePharmalot

Topics: BiotechPharmaPolicyHealth TechBusiness

Features: STAT+ Conversations CRISPR TrackrDrug Pricing Policy Cheat SheetWebinars

Events: See upcoming events

Stock exchange
Biotech

Biotech stocks are a dumpster fire. An analyst explains what’s going on

By Adam Feuerstein, Meg Tirrell and Damian Garde

Hal Barron
Biotech

Did veteran drug developer Hal Barron accomplish his mission at GSK?

By Matthew Herper

Health Tech

‘We must change’: Health systems invest more aggressively than ever in digital health

By Casey Ross

Watson on laptop
Health Tech

The sale of Watson Health assets ends a dark chapter for IBM. For its buyer, the opportunity looks brighter

By Casey Ross

Pharmalot Coming/Going STILL
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Fall of Watson
Health Tech

Once billed as a revolution in medicine, IBM’s Watson Health is sold off in parts

By Casey Ross

Pharmalot

Pharmalittle: Alzheimer’s patient groups to protest Medicare plan for Biogen drug; cancer combo treatments are questioned

By Ed Silverman

Michel Vounatsos
The Pharmalot View

If the Biogen CEO were truly ‘courageous,’ he would live with the Medicare decision

By Ed Silverman

In the Lab

New research casts doubt on how combination cancer therapies work in tandem

By Angus Chen

Pharmalot

Pharmalittle: 27 companies will make generic Merck Covid pills; drug-resistant infections are deadlier than HIV or malaria

By Ed Silverman

Pharmalot

Analysis of JAMA and NEJM articles finds most authors failed to disclose conflicts

By Ed Silverman

Pharmalot

Pharmalittle: Disease ‘reversal’ startup launches with $3 billion and biotech vets; network distributed fake Gilead HIV meds

By Ed Silverman

Sen. Wyden
Pharmalot

Senate Finance chair investigates Bristol Myers over an allegedly abusive overseas tax shelter

By Ed Silverman

Blue RNA strand
Biotech

A new RNA-based drug startup launches with Rutgers science and money connections

By Adam Feuerstein

red brain illo
Biotech

Belgian pharma UCB to buy Zogenix, maker of rare epilepsy treatment, for $1.9 billion

By Adam Feuerstein

Biotech

With $3 billion, Hal Barron and other biotech veterans launch a disease ‘reversal’ company

By Matthew Herper

Patent folder
Pharmalot

Patent thickets are thwarting U.S. availability of lower-cost biosimilar medicines, study finds

By Ed Silverman

Pharma

Bristol CEO Giovanni Caforio on new drug launches and acquisitions in 2022

By Adam Feuerstein

Pharmalot

Pharmalittle: Unilever will pursue Glaxo consumer unit despite rejection; Endo settles Florida opioid case for $65 million

By Ed Silverman

Health Tech

Wary of a backlash, telehealth startups focused on women’s sexual health steer clear of abortion pills

By Olivia Goldhill

Lehman Hall Harvard University 2016 mumps
In the Lab

Real estate developer reneges on multimillion-dollar pledge to Harvard-led Covid project

By Rebecca Ostriker and Deirdre Fernandes — The Boston Globe

Shkreli
Pharmalot

Martin Shkreli is ordered to pay $64 million and is banned from the pharma industry for life

By Ed Silverman

Pharmalot Coming/Going STILL
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Senate committee advances Califf FDA nomination; bedraggled Biogen writes a shopping list

By Ed Silverman

Opinions+

Patient engagement: The true benchmark in clinical trials

By Catherine Gregor

Aduhelm package
Politics

No one has any idea how much money seniors could pay for new Alzheimer’s drug

By Rachel Cohrs

2020 Biogen
Exclusive

With its Alzheimer’s drug in turmoil, Biogen eyes a list of potential acquisitions

By Damian Garde and Adam Feuerstein

Eye
Pharmalot

FDA warns Chinese manufacturer for lack of vision when making sterile eye drops

By Ed Silverman

telehealth rx
Health Tech

Telehealth experiments & the latest digital health news from JPM

By Mohana Ravindranath and Mario Aguilar